Post Photo

BOLD-100 Effective In Vitro Against COVID-19 Variants

VANCOUVER, BC, April 16, 2021 /PRNewswire/ -- Bold Therapeutics, a clinical-stage biopharmaceutical company developing BOLD-100, a first-in-class oncology and antiviral therapeutic, is announcing robust preclinical efficacy data against a wide range of COVID-19 variants. New in vitro research completed by Bold Therapeutics' collaborators at the University of British Columbia and Western University showed that BOLD-100 consistently reduced viral concentrations in multiple COVID-19 variants, including the highly prevalent B.1.1.7 variant originally identified in the UK (see Figure 1). This work confirms and expands upon prior research demonstrating that BOLD-100 has strong antiviral activity against COVID-19 in a range of preclinical in vitro models. Bold Therapeutics continues to advance BOLD-100 as a versatile therapeutic to improve outcomes in COVID-19 patients.

Unlike vaccines, which are specific to a particular viral strain, BOLD-100's broad antiviral mechanism-of-action appears to be unaffected by viral mutations. BOLD-100 selectively inhibits stress-induced upregulation of GRP78, a master chaperone protein that plays a critical role in viral replication. GRP78 has been identified in more than 200 academic articles as a potentially attractive antiviral target.

In December 2020, Bold Therapeutics was one of only four therapeutics companies selected by National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) for COVID-19 funding and support. Since that time, Bold Therapeutics has generated additional efficacy and safety data, including the aforementioned variant studies, and is currently completing in vivo studies of BOLD-100. In parallel, Bold Therapeutics continues to enroll patients in its Phase 1b study of BOLD-100 in the treatment of advanced gastrointestinal cancers. Including the previously completed Phase 1 monotherapy study, more than 50 cancer patients have been treated with BOLD-100, suggesting that it is generally safe and well-tolerated. As a clinical-stage product with regulatory clearance in both Canada and the U.S. to initiate clinical trials and a clean safety profile, Bold Therapeutics is uniquely positioned to advance rapidly into COVID-19 clinical trials with continued government support.

Media Contact:
E. Russell McAllister, CEO